Novanta (NOVT) Aktievy
Novanta Inc. och dess dotterbolag tillhandahåller precisionsmedicin, precisionstillverkning, medicinska lösningar, robot- och automationslösningar samt lösningar för avancerad kirurgi i USA och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 0/6 |
| Framtida tillväxt | 4/6 |
| Tidigare resultat | 2/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
NOVT Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Novanta Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$134.31 |
| 52 veckors högsta | US$176.38 |
| 52 veckors lägsta | US$98.27 |
| Beta | 1.68 |
| 1 månads förändring | -7.53% |
| 3 månaders förändring | -11.25% |
| 1 års förändring | 18.67% |
| 3 års förändring | -3.67% |
| 5 års förändring | -18.37% |
| Förändring sedan börsintroduktionen | 742.72% |
Senaste nyheter och uppdateringar
Seeking Alpha • Aug 23
Novanta: A Strong Year So Far, Fully Priced In
Summary Novanta completed the Riverpoint Medical acquisition, enhancing recurring consumables and medical business growth prospects. Q2 sales rose 10% to $266M with 9% organic growth and adjusted EBITDA up 16%, reflecting strong operational performance. Forward guidance projects 2026 sales of $1.135B and adjusted earnings of $3.71 per share, with Riverpoint contributing $0.18-$0.25 EPS in 2027. Despite improved fundamentals and backlog, Novanta trades at a demanding 36-37x forward earnings, keeping risk-reward only modestly improved. Read the full article on Seeking Alpha
Uppdatering av berättelse • Aug 22
NOVT: Future Returns Will Depend On Executing Medical Acquisition And Restructuring Strategy
Analysts have lifted their price target on Novanta to $194.50 from $182, citing updated valuation work after Q2 results and the stock's inclusion on a conviction list as key supports for the new view. Analyst Commentary Recent research updates around Novanta highlight how analysts are thinking about the stock after the latest Q2 results and its inclusion on an analyst conviction list.Uppdatering av berättelse • Aug 08
NOVT: Future Returns Will Hinge On Executing Medical Acquisition And Restructuring Plans
Novanta's updated fair value estimate has increased from $175 to $182, reflecting analysts' higher price targets and refreshed models following recent earnings updates and the stock's addition to a conviction list. Analyst Commentary Recent Street research on Novanta points to a generally constructive view on the stock, with analysts updating their models after Q1 and Q2 results and after the company was added to an Analyst Conviction List.Recent updates
Seeking Alpha • Aug 23
Novanta: A Strong Year So Far, Fully Priced In
Summary Novanta completed the Riverpoint Medical acquisition, enhancing recurring consumables and medical business growth prospects. Q2 sales rose 10% to $266M with 9% organic growth and adjusted EBITDA up 16%, reflecting strong operational performance. Forward guidance projects 2026 sales of $1.135B and adjusted earnings of $3.71 per share, with Riverpoint contributing $0.18-$0.25 EPS in 2027. Despite improved fundamentals and backlog, Novanta trades at a demanding 36-37x forward earnings, keeping risk-reward only modestly improved. Read the full article on Seeking AlphaUppdatering av berättelse • Aug 22
NOVT: Future Returns Will Depend On Executing Medical Acquisition And Restructuring Strategy
Analysts have lifted their price target on Novanta to $194.50 from $182, citing updated valuation work after Q2 results and the stock's inclusion on a conviction list as key supports for the new view. Analyst Commentary Recent research updates around Novanta highlight how analysts are thinking about the stock after the latest Q2 results and its inclusion on an analyst conviction list.Uppdatering av berättelse • Aug 08
NOVT: Future Returns Will Hinge On Executing Medical Acquisition And Restructuring Plans
Novanta's updated fair value estimate has increased from $175 to $182, reflecting analysts' higher price targets and refreshed models following recent earnings updates and the stock's addition to a conviction list. Analyst Commentary Recent Street research on Novanta points to a generally constructive view on the stock, with analysts updating their models after Q1 and Q2 results and after the company was added to an Analyst Conviction List.Uppdatering av berättelse • Jun 17
NOVT: Future Earnings Power Will Rely On Executing Riverpoint Acquisition Strategy
Analysts have adjusted their fair value estimate for Novanta to $175.0 from $171.5, citing updated models that incorporate recent Q1 results, accelerating bookings and growth momentum, along with a revised future P/E assumption of 34.67x. Analyst Commentary Recent Street commentary on Novanta focuses on how the latest Q1 results and updated models feed into valuation, execution risk and future growth assumptions for the stock.Uppdatering av berättelse • Jun 02
NOVT: Future Earnings Power Will Rely On Sustaining Bookings Strength And Margin Execution
Analysts have lifted their fair value estimate for Novanta stock from $157 to about $171.50, citing updated models that reflect Q1 results with accelerating bookings and ongoing growth momentum. Analyst Commentary Bullish Takeaways Bullish analysts point to accelerating Q1 bookings as a key support for a higher fair value range, seeing healthier near term demand feeding into updated models.Analysartikel • May 15
Novanta Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
It's been a pretty great week for Novanta Inc. ( NASDAQ:NOVT ) shareholders, with its shares surging 14% to US$156 in...Uppdatering av berättelse • Apr 19
NOVT: Future Earnings Power Will Rely On Executing Stronger Margins
Narrative update on Novanta The consensus analyst price target for Novanta has been raised by $12 to $150. Analysts cite updated models after Q4 results that indicate potential for stronger sales and margin performance.Uppdatering av berättelse • Apr 05
NOVT: Future Earnings Power Will Rely On Accelerating Sales And Margins
Analysts have trimmed their fair value estimate for Novanta from $160 to $157, reflecting a slightly higher discount rate and a modestly lower future P/E assumption, while still pointing to expectations for improving sales and margins after recent model updates. Analyst Commentary Bullish Takeaways Bullish analysts see room for the shares to move toward their updated fair value range, supported by model revisions that assume improving sales trends and margin recovery after recent results.Uppdatering av berättelse • Mar 22
NOVT: Future Earnings Power Will Rely On Accelerating Margins
Analysts have lifted their price target on Novanta to $150 from $138, citing updated Q4 models that suggest the company may be positioned for faster sales growth and margin expansion. Analyst Commentary Bullish Takeaways Bullish analysts point to the raised price target to $150 as a sign that updated Q4 assumptions support a higher valuation range for the shares.Uppdatering av berättelse • Mar 06
NOVT: Future Earnings Power Will Rely On Accelerating Margins
Analysts have lifted their fair value estimate for Novanta to $160 from $154, supported by updated models that reflect expectations for accelerating sales and margins following recent Q4 results and a higher Street price target of $150 from $138. Analyst Commentary Recent commentary points to a more constructive view on Novanta following its Q4 results, with updated models feeding into a higher fair value framework and a Street price target of $150.Uppdatering av berättelse • Feb 20
NOVT: Stable Outlook Will Rely On Steady Margins And Earnings Multiple
Narrative Update: Novanta Analyst Price Target The analyst price target for Novanta is unchanged at $154, as analysts keep their assumptions for fair value, discount rate, revenue growth, profit margin and future P/E essentially steady. Valuation Changes Fair Value: $154.00 remains effectively unchanged compared with the prior estimate of $154.Uppdatering av berättelse • Feb 06
NOVT: Equity Units Offering Will Support Balance Sheet And Future Deals
Analysts have nudged their price target on Novanta slightly higher to reflect modest tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions, framing the move as fine tuning rather than a major reset in expectations. What's in the News Novanta plans to look for acquisitions and investments, signaling an interest in adding to its portfolio of businesses (Key Developments).Uppdatering av berättelse • Jan 22
NOVT: Equity Units And Share Repurchases Will Support Balance Sheet And Future Deals
Analysts now keep their price target for Novanta effectively unchanged at about $154.00. They point to steady assumptions around discount rate, revenue growth, profit margin and future P/E as the key drivers of their view.Uppdatering av berättelse • Jan 08
NOVT: Equity Units Offering Will Strengthen Balance Sheet And Support Future Deals
Analysts have maintained their fair value estimate for Novanta at approximately $154. They cite only marginal adjustments to the discount rate, long term revenue growth, profit margin assumptions, and future P/E, which do not materially change their overall outlook.Uppdatering av berättelse • Dec 24
NOVT: New Equity Raise Will Strengthen Balance Sheet And Support Future Deals
Analysts have maintained their price target for Novanta at approximately $154 per share. This reflects a steady outlook, as incremental adjustments to discount rate assumptions and long term growth and profitability estimates are viewed as too minor to warrant a change in fair value.Uppdatering av berättelse • Dec 10
NOVT: Expanded Equity Offering And Buybacks Will Drive Long Term Shareholder Value
Analysts have nudged their price target for Novanta slightly higher to align with its updated fair value of $154.00, reflecting modestly stronger confidence in the company’s steady growth and margin profile. What's in the News Novanta completed a $550 million composite tangible equity units offering, issuing 11 million units priced at $50 each, with a $1.375 discount per unit (Key Developments).Uppdatering av berättelse • Nov 26
NOVT: Expanded Buyback Authorization Will Increase Shareholder Value Going Forward
Narrative Update on Novanta: Analyst Price Target Change Analysts have maintained Novanta's fair value estimate at $154. They cited improved profitability metrics, which offset slight adjustments in the discount rate and growth projections.Uppdatering av berättelse • Nov 10
NOVT: Equity Buyback Expansion And Profit Margin Gains Will Drive Upside
Analysts have raised their fair value estimate for Novanta from $141.50 to $154.00 per share, citing expectations for stronger future revenue growth and improved profit margins, even though the discount rate is slightly higher. What's in the News Novanta Inc.Analysartikel • Oct 28
Novanta Inc. (NASDAQ:NOVT) Looks Just Right With A 30% Price Jump
Novanta Inc. ( NASDAQ:NOVT ) shares have had a really impressive month, gaining 30% after a shaky period beforehand...Analysartikel • Oct 07
Is Now The Time To Look At Buying Novanta Inc. (NASDAQ:NOVT)?
Novanta Inc. ( NASDAQ:NOVT ), is not the largest company out there, but it received a lot of attention from a...Uppdatering av berättelse • Sep 05
Robotics And Healthcare Demand Will Expand Market Opportunities
Novanta’s fair value outlook remains unchanged, as both the discount rate and future P/E shifted only marginally, leaving the consensus analyst price target steady at $141.50. What's in the News Novanta projects third quarter 2025 GAAP revenue of $244 million to $247 million and full year 2025 GAAP revenue of $970 million to $985 million.Seeking Alpha • Apr 06
Novanta: A Trusted Yet Premium Technology Partner
Summary Novanta has shown solid growth over the past decade, but growth has been a bit sluggish in recent years. The company is a key technology partner for global OEMs, with balanced revenue from advanced industrial and medical applications, boasting strong EBITDA margins. Despite a recent acquisition and increased sales, competitive dynamics, and macroeconomic challenges have pressured growth; shares are now trading at a lower, yet still premium, multiple. With debt reduced and growth returning, shares deserve a premium, but need to fall below $100 for a more attractive valuation. Read the full article on Seeking AlphaSeeking Alpha • Jan 01
Novanta: Delayed Recovery And Prolonged Struggles Ahead, Downgrade To Sell
Summary Novanta's Q3 results show revenue growth but a decline in gross margin and shipment deferrals, indicating prolonged challenges. Macroeconomic pressures, including weak demand and high interest rates, are hindering recovery in the life sciences sector. The company's book-to-bill ratio below 1 signals weakening demand, and its high debt levels add to the risk. Novanta’s valuation is too high given its low growth prospects, especially compared to more promising peers. As a result of these factors, Novanta is downgraded from a hold to a sell, as its current price does not justify the risks. Read the full article on Seeking AlphaSeeking Alpha • Sep 02
Novanta Inc.: Overpriced In A Weak Demand Market. Here's Why It's A Hold
Summary Novanta Inc. is a leading tech provider facing macroeconomic headwinds and a soft demand climate, which have pressured its revenue and profitability. Despite strong fundamentals and a solid market position, its current high valuation makes it a risky investment. NOVT has managed modest revenue growth but struggles with significant inflationary challenges. For now, a Hold rating is recommended as the stock's valuation does not align with its performance amidst ongoing market uncertainties. Read the full article on Seeking Alpha
Ny berättelse • Aug 28
Innovative Medical Devices And Tactical Acquisitions Poised To Accelerate Company Growth
Focusing on medical devices with new products might significantly boost future revenue through innovation, aiming for notable revenue from new launches by 2025.Aktieägarnas avkastning
| NOVT | US Electronic | US Marknad | |
|---|---|---|---|
| 7D | -4.1% | 5.4% | 1.8% |
| 1Y | 18.7% | 41.5% | 13.3% |
Avkastning vs industri: NOVT presterade sämre än US Electronic branschen som gav 41.5 % under det senaste året.
Avkastning vs Marknaden: NOVT översteg US marknaden som gav 13.3 % under det senaste året.
Prisvolatilitet
| NOVT volatility | |
|---|---|
| NOVT Average Weekly Movement | 6.8% |
| Electronic Industry Average Movement | 8.9% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stabil aktiekurs: NOVT har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: NOVT s veckovolatilitet ( 7% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1968 | 3,000 | Matthijs Glastra | www.novanta.com |
Novanta Inc. och dess dotterbolag tillhandahåller precisionsmedicin, precisionstillverkning, medicinska lösningar, robotik- och automationslösningar samt avancerade kirurgilösningar i USA och internationellt. Bolaget är verksamt inom segmenten Automation Enabling Technologies och Medical Solutions. Segmentet Precision Medicine and Manufacturing designar, tillverkar och marknadsför lösningar för styrning och skanning av laserstrålar, laserkällor, robot- och precisionsrörelser, verktyg för robotar i slutet av armar samt lagerspindlar.
Novanta Inc. Sammanfattning av grunderna
| NOVT grundläggande statistik | |
|---|---|
| Börsvärde | US$5.04b |
| Vinst(TTM) | US$61.76m |
| Intäkter(TTM) | US$1.03b |
82.2x
P/E-förhållande4.9x
P/S-förhållandeÄr NOVT övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| NOVT resultaträkning (TTM) | |
|---|---|
| Intäkter | US$1.03b |
| Kostnad för intäkter | US$571.02m |
| Bruttovinst | US$458.68m |
| Övriga kostnader | US$396.91m |
| Intäkter | US$61.76m |
Senast redovisade vinst
Jul 03, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 1.63 |
| Bruttomarginal | 44.54% |
| Nettovinstmarginal | 6.00% |
| Skuld/egenkapitalförhållande | 14.2% |
Hur har NOVT utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/09/21 09:06 |
| Aktiekurs vid dagens slut | 2026/09/21 00:00 |
| Intäkter | 2026/07/03 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Novanta Inc. bevakas av 8 analytiker. 3 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Robert Mason | Baird |
| Quinn Fredrickson | Baird |
| Andrew Buscaglia | Berenberg |